A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

Patients with asymptomatic (smoldering) multiple myeloma (AMM) have a high risk of transformation to active multiple myeloma (MM). Bisphosphonates such as zoledronic acid (ZLD) reduce skeletal events in MM and the immunomodulatory agent thalidomide (Thal) has proven effectiveness in active MM. We hy...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Witzig, TE, Laumann, KM, Lacy, MQ, Hayman, SR, Dispenzieri, A, Kumar, S, Reeder, CB, Roy, V, Lust, JA, Gertz, MA, Greipp, PR, Hassoun, H, Mandrekar, SJ, Rajkumar, SV
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2012
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3912579/
https://ncbi.nlm.nih.gov/pubmed/22902362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2012.236
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller